STRATIFYING CARDIAC RISK IN ASYMPTOMATIC INDIVIDUALS

Existing cardiovascular risk prediction models have specific limitations, such as applicability only in certain populations and the ability to measure only a limited number of cardiovascular outcomes.

Abbott's high sensitive troponin-I blood test can more accurately predict which asymptomatic individual is likely to be at low, moderate or elevated risk for future adverse cardiac events. It enables the care of those at higher risk to be prioritized to help prevent adverse outcomes.

ANALYZING THE CLINICAL EVIDENCE

The Physician's Resource e-book contains findings from notable medical studies demonstrating the clinical utility of Abbott's high sensitive troponin-I test in the assessment of cardiovascular risk.

Featured clinical studies and trials include:

• Nord-Trøndelag Health (Hunt) Study
• West of Scotland Coronary Prevention Study
• Biomarkers from Cardiovascular Risk Assessment in Europe (Biomarcare) Project
• The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial